Lataa...
Blinatumomab: a bispecific T cell engager (BiTE) antibody against CD19/CD3 for refractory acute lymphoid leukemia
Targeted therapy has been the forefront of cancer treatment. Cancer immunotherapy is the most recent focus. In addition, novel immunotherapeutics targeting B cell receptor signaling (e.g., ibrutinib), T cell receptor ( e.g., CART19), and NK cells (e.g., AFM13) are being developed. This review summar...
Tallennettuna:
| Julkaisussa: | J Hematol Oncol |
|---|---|
| Päätekijät: | , , , |
| Aineistotyyppi: | Artigo |
| Kieli: | Inglês |
| Julkaistu: |
BioMed Central
2015
|
| Aiheet: | |
| Linkit: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4558758/ https://ncbi.nlm.nih.gov/pubmed/26337639 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s13045-015-0195-4 |
| Tagit: |
Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!
|